ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas

Trial Profile

ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Sponsors Oncoceutics
  • Most Recent Events

    • 02 Feb 2018 New trial record
    • 31 Jan 2018 According to an Oncoceutics media release, the first patient has been dosed in this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top